Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Human Factors

Date Submitted: Apr 6, 2022
Open Peer Review Period: Apr 6, 2022 - May 3, 2022
Date Accepted: Jun 4, 2022
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Remotely Conducted App-Based Intervention for Cardiovascular Disease and Diabetes Risk Awareness and Prevention: Single-Group Feasibility Trial

Buss VH, Varnfield M, Harris M, Barr M

Remotely Conducted App-Based Intervention for Cardiovascular Disease and Diabetes Risk Awareness and Prevention: Single-Group Feasibility Trial

JMIR Hum Factors 2022;9(3):e38469

DOI: 10.2196/38469

PMID: 35776504

PMCID: 9288098

Remotely Conducted App-based Intervention for Cardiovascular and Diabetes Risk Awareness and Prevention: Feasibility Study

  • Vera Helen Buss; 
  • Marlien Varnfield; 
  • Mark Harris; 
  • Margo Barr

ABSTRACT

Background:

Cardiovascular disease and type 2 diabetes mellitus are 2 of the most prevalent chronic conditions worldwide. An unhealthy lifestyle greatly contributes to someone’s risk of developing the conditions. Mobile health is an emerging technology that can help deliver health promotion interventions to the population, for example, in the form of health apps.

Objective:

To test the feasibility of an app-based intervention for cardiovascular and diabetes risk awareness and prevention by measuring non-usage, drop-out, adherence to app use, and usability of the app over 3 months.

Methods:

Participants were eligible if they were aged 45 years or older, resided in Australia, were free of cardiovascular disease and diabetes, were fluent in English, and owned a smartphone. In the beginning, participants received an email with instructions on how to install the app and a user guide. After 3 months, they received an email with an invitation to an end-of-study survey. The survey included questions about general smartphone use and the user version of the Mobile Application Rating Scale. We analyzed app-generated and survey data using descriptive and inferential statistics as well as thematic analysis for open-text comments.

Results:

Recruitment took place between September and October 2021. Of the 46 participants who consented to the study, 20 participants never used the app (44%) and 15 participants dropped out (33%). The median age of app users at baseline was 62 years (IQR 56‒67). Adherence to app use, that is, using the app at least once a week over 3 months, was 17% (8/46) of the total sample and 31% (8/26) of all app users. The mean app quality rating on the user version of the Mobile Application Rating Scale was 3.5 of 5 points (SD 0.6). The app scored highest for the information section and lowest for the engagement section of the scale.

Conclusions:

Non-usage and drop-out were too high and the adherence too low to consider the intervention in its current form feasible. Potential barriers we identified include the research team not actively engaging with participants early in the study to verify that all participants could install the app, that the intervention did not involve direct contact with healthcare professionals, and that the app did not have enough interactive interaction features.


 Citation

Please cite as:

Buss VH, Varnfield M, Harris M, Barr M

Remotely Conducted App-Based Intervention for Cardiovascular Disease and Diabetes Risk Awareness and Prevention: Single-Group Feasibility Trial

JMIR Hum Factors 2022;9(3):e38469

DOI: 10.2196/38469

PMID: 35776504

PMCID: 9288098

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.